Nemo-Like Kinase Antikörper (AA 278-527)

Produktnummer ABIN7169124

Produktdetails anti-Nemo-Like Kinase Antikörper

Target: Nemo-Like Kinase (NLK)

Bindungsspezifität: AA 278-527

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Nemo-Like Kinase Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC)

Kreuzreaktivität: Human

Aufreinigung: Antigen Affinity Purified

Immunogen: Recombinant Human Serine/threonine-protein kinase NLK protein (278-527AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu Nemo-Like Kinase

Target: Nemo-Like Kinase (NLK)

Andere Bezeichnung: NLK (NLK Produkte)

Synonyme: Amf antikoerper, Gpi1 antikoerper, AI194375 antikoerper, nlk antikoerper, nlkb antikoerper, zgc:111875 antikoerper, Xnlk antikoerper, nlk1 antikoerper, nlk2 antikoerper, NLK antikoerper, nemo-like antikoerper, RGD1561602 antikoerper, glucose-6-phosphate isomerase antikoerper, nemo like kinase antikoerper, nemo-like kinase, type 1 antikoerper, nemo-like kinase L homeolog antikoerper, Nemo-Like kinase antikoerper, nemo-like kinase antikoerper, Gpi antikoerper, NLK antikoerper, Nlk antikoerper, nlk1 antikoerper, nlk.L antikoerper, nlk antikoerper, nemo-like antikoerper

Hintergrund:

Background: Serine/threonine-protein kinase that regulates a number of transcription factors with key roles in cell fate determination. Positive effector of the non-canonical Wnt signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Activation of this pathway causes binding to and phosphorylation of the histone methyltransferase SETDB1. The NLK-SETDB1 complex subsequently interacts with PPARG, leading to methylation of PPARG target promoters at histone H3K9 and transcriptional silencing. The resulting loss of PPARG target gene transcription inhibits adipogenesis and promotes osteoblastogenesis in mesenchymal stem cells (MSCs). Negative regulator of the canonical Wnt/beta-catenin signaling pathway. Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as well as the ubiquitination and subsequent proteolysis of LEF1. Together these effects inhibit the transcriptional activation of canonical Wnt/beta-catenin target genes. Negative regulator of the Notch signaling pathway. Binds to and phosphorylates NOTCH1, thereby preventing the formation of a transcriptionally active ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of transcription factors. Phosphorylation of MYB leads to its subsequent proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their interaction with the coactivator CREBBP. Other transcription factors may also be inhibited by direct phosphorylation of CREBBP itself. Acts downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B stimulus, cooperates with ATF5 to activate the transactivation activity of C/EBP subfamily members. Phosphorylates ATF5 but also stabilizes ATF5 protein levels in a kinase-independent manner (PubMed:25512613).

Aliases: DKFZp761G1211 antibody, FLJ21033 antibody, LAK1 antibody, Nemo like kinase antibody, Nemo-like kinase antibody, Nlk antibody, NLK_HUMAN antibody, Protein LAK1 antibody, Serine/threonine protein kinase NLK antibody, Serine/threonine-protein kinase NLK antibody

UniProt: Q9UBE8

Pathways: Ubiquitin Proteasome Pathway